Matthew Ku

1.7k total citations · 1 hit paper
47 papers, 821 citations indexed

About

Matthew Ku is a scholar working on Pathology and Forensic Medicine, Oncology and Genetics. According to data from OpenAlex, Matthew Ku has authored 47 papers receiving a total of 821 indexed citations (citations by other indexed papers that have themselves been cited), including 35 papers in Pathology and Forensic Medicine, 25 papers in Oncology and 23 papers in Genetics. Recurrent topics in Matthew Ku's work include Lymphoma Diagnosis and Treatment (35 papers), CAR-T cell therapy research (21 papers) and Chronic Lymphocytic Leukemia Research (20 papers). Matthew Ku is often cited by papers focused on Lymphoma Diagnosis and Treatment (35 papers), CAR-T cell therapy research (21 papers) and Chronic Lymphocytic Leukemia Research (20 papers). Matthew Ku collaborates with scholars based in Australia, United States and Canada. Matthew Ku's co-authors include Chan Y. Cheah, Lihua E. Budde, Nancy L. Bartlett, Sarit Assouline, Stephen J. Schuster, Michael C. Wei, Shen Yin, Antonia Kwan, Laurie H. Sehn and Matthew J. Matasar and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

Matthew Ku

41 papers receiving 810 citations

Hit Papers

Safety and efficacy of mosunetuzumab, a bispecific antibo... 2022 2026 2023 2024 2022 50 100 150 200
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study
    2022 244 citations Lihua E. Budde, Laurie H. Sehn et al. The Lancet Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Matthew Ku Australia 12 531 526 262 184 165 47 821
Manali Kamdar United States 17 818 1.5× 1.1k 2.0× 286 1.1× 211 1.1× 157 1.0× 90 1.4k
David Belada Czechia 18 819 1.5× 604 1.1× 327 1.2× 176 1.0× 162 1.0× 167 1.1k
Craig A. Portell United States 16 409 0.8× 322 0.6× 281 1.1× 156 0.8× 55 0.3× 65 765
Juan Pablo Alderuccio United States 13 538 1.0× 487 0.9× 159 0.6× 99 0.5× 131 0.8× 79 749
Guiyuan Lei United Kingdom 12 509 1.0× 343 0.7× 480 1.8× 228 1.2× 209 1.3× 28 891
Martha Glenn United States 15 334 0.6× 275 0.5× 250 1.0× 138 0.8× 87 0.5× 41 813
Jamie Hirata United States 17 1.1k 2.0× 1.0k 2.0× 425 1.6× 215 1.2× 224 1.4× 64 1.4k
Kamal Bouabdallah France 11 439 0.8× 350 0.7× 237 0.9× 100 0.5× 76 0.5× 27 531
Ciara L. Freeman United States 15 335 0.6× 451 0.9× 173 0.7× 134 0.7× 75 0.5× 87 934
Beata Holkova United States 13 297 0.6× 307 0.6× 139 0.5× 87 0.5× 49 0.3× 48 634

Countries citing papers authored by Matthew Ku

Since Specialization
Citations

This map shows the geographic impact of Matthew Ku's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Matthew Ku with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Matthew Ku more than expected).

Fields of papers citing papers by Matthew Ku

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Matthew Ku. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Matthew Ku. The network helps show where Matthew Ku may publish in the future.

Co-authorship network of co-authors of Matthew Ku

This figure shows the co-authorship network connecting the top 25 collaborators of Matthew Ku. A scholar is included among the top collaborators of Matthew Ku based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Matthew Ku. Matthew Ku is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Abramson, Jeremy S., Matthew Ku, Mark Hertzberg, et al.. (2025). Glofitamab plus gemcitabine and oxaliplatin (Glofit-GemOx) in patients (pts) with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): 2-year (yr) follow-up of STARGLO.. Journal of Clinical Oncology. 43(16_suppl). 7015–7015.
2.
Asch, Adam S., Leslie Popplewell, Graham P. Collins, et al.. (2024). Magrolimab plus rituximab with or without chemotherapy in patients with relapsed/refractory diffuse large B-cell lymphoma. Blood Advances. 8(22). 5864–5874. 6 indexed citations
3.
4.
Ladetto, Marco, Matthew Ku, Luca Arcaini, et al.. (2024). Mosunetuzumab and Zanubrutinib in Relapsed/Refractory Follicular Lymphoma Patients (MOZART): A Phase II, Chemo-Free Trial from Fondazione Italiana Linfomi (FIL). Blood. 144(Supplement 1). 3042.1–3042.1. 1 indexed citations
5.
Barraclough, Allison, Catherine Tang, Masa Lasica, et al.. (2024). Diagnosis and management of mantle cell lymphoma: a consensus practice statement from the Australasian Lymphoma Alliance. Internal Medicine Journal. 55(1). 117–129.
6.
Minson, Adrian, Nada Hamad, Dipti Talaulikar, et al.. (2023). Death from mantle cell lymphoma limits sequential therapy, particularly after first relapse: Patterns of care and outcomes in a series from Australia and the United Kingdom. British Journal of Haematology. 204(2). 548–554. 3 indexed citations
7.
Polizzotto, Mark N., Sam Milliken, Tara Cochrane, et al.. (2023). Outcomes of human immunodeficiency virus‐associated Burkitt lymphoma and diffuse large B‐cell lymphoma treated in Australia: A report from the Australasian Lymphoma Alliance. British Journal of Haematology. 201(5). 865–873. 4 indexed citations
8.
Tam, Constantine S., et al.. (2023). T-Cell Engaging Antibodies in Diffuse Large B Cell Lymphoma—An Update. Journal of Clinical Medicine. 12(21). 6737–6737. 4 indexed citations
9.
10.
Nowakowski, Grzegorz S., Dok Hyun Yoon, Anthea Peters, et al.. (2022). Improved Efficacy of Tafasitamab plus Lenalidomide versus Systemic Therapies for Relapsed/Refractory DLBCL: RE-MIND2, an Observational Retrospective Matched Cohort Study. Clinical Cancer Research. 28(18). 4003–4017. 16 indexed citations
11.
Budde, Lihua E., Laurie H. Sehn, Matthew J. Matasar, et al.. (2022). Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study. The Lancet Oncology. 23(8). 1055–1065. 244 indexed citations breakdown →
12.
Wight, Joel, Nada Hamad, Belinda A. Campbell, et al.. (2021). Diffuse large B‐cell lymphoma: a consensus practice statement from the Australasian Lymphoma Alliance. Internal Medicine Journal. 52(9). 1609–1623. 3 indexed citations
13.
Matasar, Matthew J., Chan Y. Cheah, Dok Hyun Yoon, et al.. (2020). Subcutaneous Mosunetuzumab in Relapsed or Refractory B-Cell Lymphoma: Promising Safety and Encouraging Efficacy in Dose Escalation Cohorts. Blood. 136(Supplement 1). 45–46. 27 indexed citations
14.
Gregory, Gareth P., Constantine S. Tam, Hang Quach, et al.. (2020). Excellent outcomes in older patients with primary CNS lymphoma treated with R-MPV/cytarabine without whole brain radiotherapy or autologous stem cell transplantation therapy. Leukemia & lymphoma. 62(1). 112–117. 8 indexed citations
15.
16.
Ku, Matthew, et al.. (2020). Acquired Pure Red Cell Aplasia Associated with Chronic Myelomonocytic Leukemia: Too Many of One, Not Enough of the Other. Case Reports in Oncology. 13(3). 1270–1274. 1 indexed citations
17.
Ku, Matthew, Ruth N. MacKinnon, Meaghan Wall, et al.. (2019). Hemopoietic Cell Kinase amplification with Protein Tyrosine Phosphatase Receptor T depletion leads to polycythemia, aberrant marrow erythoid maturation, and splenomegaly. Scientific Reports. 9(1). 7050–7050. 4 indexed citations
18.
Ku, Matthew, et al.. (2016). Tumour cell surface antigen targeted therapies in B-cell lymphomas: Beyond rituximab. Blood Reviews. 31(1). 23–35. 11 indexed citations
19.
20.
Ku, Matthew, Meaghan Wall, Ruth N. MacKinnon, et al.. (2014). Src family kinases and their role in hematological malignancies. Leukemia & lymphoma. 56(3). 577–586. 23 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Manali Kamdar Breakdown of academic impact, for papers by David Belada Breakdown of academic impact, for papers by Craig A. Portell Breakdown of academic impact, for papers by Juan Pablo Alderuccio Breakdown of academic impact, for papers by Guiyuan Lei Breakdown of academic impact, for papers by Martha Glenn Breakdown of academic impact, for papers by Jamie Hirata Breakdown of academic impact, for papers by Kamal Bouabdallah Breakdown of academic impact, for papers by Ciara L. Freeman Breakdown of academic impact, for papers by Beata Holkova
Rankless by CCL
2026